Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

• Main Authors: Tim R. Cressey, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham, Jennifer R. King, Paula Britto, Vincent J. Carey, Edward P. Acosta, Ram Yogev
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84984700603&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/56010
• Institution: Chiang Mai University

© 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.